Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. With our transformation into a fully integrated oncology company well underway, it’s an exciting time to be part of Team Olema.

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from OPERA-01, our ongoing Phase 3 trial of palazestrant as a monotherapy in patients with second- or third-line ER+/HER2- metastatic breast cancer (MBC), in Q1 2027 which, if positive, could lead to our first potential approval and commercial launch in 2028. OPERA-02, our Phase 3 trial of palazestrant in combination with ribociblib in patients with frontline ER+/HER2- MBC, is enrolling patients. Together with its mechanism of action, pharmacokinetic properties, and the potential to demonstrate activity in both ESR1 wild-type and mutant tumors, palazestrant could transform the metastatic breast cancer treatment paradigm and provide access to a $15 billion global market opportunity.

Our follow-on product candidate, OP-3136, is a potent KAT6 inhibitor with the potential to generate further value and meaningfully impact the metastatic breast cancer treatment landscape – particularly in combination with palazestrant. We recently presented encouraging Phase 1 monotherapy data from this program across multiple solid tumor types, are advancing patient enrollment in the ongoing combination arms in MBC, and expect to initiate a Phase 1 study of OP-3136 in combination with Bayer’s darolutamide in metastatic castration-resistant prostate cancer by the end of this year.

Aspiring to transform the metastatic treatment paradigm is an ambitious endeavor that requires a resolute approach to developing better therapies and passionate colleagues dedicated to helping the patients we serve feel better, longer. Team Olema possesses a deep commitment to a shared purpose, the sustained pursuit of excellence, cultivating the courage required to advance our programs, the drive to succeed, and a collective capacity for adaptability through learning, growth, and evolution. We are a small group of nimble self-starters who bring consistency in our quest for the extraordinary every single day.

If you’re ready to be part of a tenacious, courageous, agile, and growing team, join us in making a profound impact, together – for our patients, for your career, and for what’s beyond.

About the Role >>> Executive Assistant, supporting Chief Financial Officer

We are seeking a highly motivated, resourceful, and experienced Executive Assistant to support our Chief Financial Officer (CFO) and approximately 4–6 senior leaders within the organization. This is a highly visible role that requires exceptional organizational skills, sound judgment, discretion, communication excellence, and the ability to effectively manage multiple priorities in a fast-paced, collaborative environment.

The Executive Assistant will provide seamless administrative support across the CFO leadership team, balancing the needs of multiple executives while helping ensure day-to-day operations run smoothly. You will manage communications and coordinate activities with internal and key external parties, including investors and board members. You will be a trusted partner to the CFO and leadership team, as well as a valued member of the broader Executive Assistant team, collaborating with colleagues to provide outstanding support across the organization.

If you are organized, proactive, collaborative, and energized by supporting executives in a dynamic environment, particularly within the biotechnology or pharmaceutical industry this is a unique opportunity to contribute to our mission to develop innovative medicines for breast cancer and beyond.

This role is based in our San Francisco, CA office and requires an on-site presence four days per week.

Your work will primarily encompass:

Executive Support

Provide day-to-day administrative support to the Chief Financial Officer (CFO) and approximately 4–6 senior leaders.
Manage complex calendars for multiple executives, balancing competing priorities and coordinating meetings across internal and external stakeholders, including with investors and other key external parties.
Coordinate meetings and events, including scheduling, conference room management, agendas, meeting materials, presentations, catering, and follow-up as needed.
Coordinate external investor and scientific events, including venues, travel, accommodation, meals and other activities as necessary to ensure success.
Arrange complex domestic and international travel, prepare detailed itineraries, and process expense reports through Concur.
Ensure executives are well prepared for internal and external meetings by coordinating materials, presentations, and other supporting documentation.
Serve as a primary point of contact for internal and external stakeholders, including members of the executive team, Board members, investors, consultants, business partners, and vendors.

Administrative Support & Team Collaboration

Build strong partnerships with cross-functional teams to coordinate schedules, meetings, and other business activities.
Partner closely with the Executive Assistant team to coordinate executive schedules, share best practices, and provide coverage as needed.
Support leadership meetings, team meetings, offsites, executive visits, candidate interviews, and other special events.
Process purchase orders, onboard vendors, and manage invoices and other administrative activities.
Help maintain an organized, productive, and welcoming office environment, including conference room coordination and office support as needed.
Handle confidential and sensitive information with professionalism, discretion, and sound judgment.
Demonstrate flexibility in supporting changing business priorities and the evolving needs of the CFO's organization.

Ideal Candidate Profile >>>

A love of challenging, important work. We are a pragmatic team, driven to imagine and develop meaningful therapies for improving lives. All employees within our company play a unique and crucial role in our success, both in accomplishing our mission and building a positive company culture. As such, we are looking for someone with the right combination of knowledge, experience, and attributes for this role.

Knowledge

Bachelor's degree strongly preferred.
Advanced proficiency with Microsoft Office, including Outlook, Teams, Excel, and PowerPoint, as well as Zoom, Concur, and other business systems.

Experience

5+ years of experience supporting C-suite executives and senior leaders, including Vice Presidents and/or Senior Directors.
Experience working in the biotechnology or pharmaceutical industry required.
Experience supporting investor relations activities required.
Demonstrated success managing multiple priorities in a fast-paced environment with changing business needs.

Attributes

Exceptional organizational skills with strong attention to detail and the ability to manage complex calendars, meetings, travel, and logistics for multiple executives.
Excellent written and verbal communication skills, and strong interpersonal skills to interface with key stakeholders.
Strong judgment, problem-solving skills, and the ability to anticipate needs and proactively resolve issues.
Ability to handle confidential information with the highest level of discretion.
Positive, proactive, and resourceful with a strong sense of ownership and accountability.
Flexible and adaptable, with the ability to manage multiple priorities and shifting business needs.
Collaborative team player who builds strong relationships across functions and levels.
Calm, composed, and solutions-oriented under pressure.

The base pay range for this position is expected to be $120,000 - $150,000 annually, however the base pay offered may vary depending on location, market, job related knowledge, skills and capabilities, and experience. The total compensation package for this position also includes equity, bonus, and benefits.

#LI-AD1

Important Information >>>

We provide equal opportunity to all employees and applicants for employment and believe that great ideas and discoveries come from a mix of expertise, background, and experience. Olema is building a culture where the value of difference is celebrated.

We offer a competitive compensation and benefits package, seeking to provide an open, flexible, and friendly work environment to empower employees and provide them with a platform to develop their long-term careers. A Summary of Benefits is available for all applicants.

Please note: Olema doesn’t accept agency resumes and is not responsible for any fees related to unsolicited resumes. Thank you.

Fraud Alert: We are aware of employment scams where individuals pose as representatives of Olema Oncology and make false use of our company name to defraud job seekers. To protect yourself, please note that Olema’s official email addresses end in @olema.com. Our official corporate website is olema.com; our careers page is olema.com/careers; our LinkedIn page is linkedin.com/company/olema-oncology. Please visit these links for official information from Olema. Communication from any other variant is fraudulent. Olema does not conduct interviews via text message/messaging platforms, will not ask you to download anything as part of your interview, will never request any form of payment, provide upfront payments of any kind, and does not make job offers without an in-person interview.

About the company

Olema Oncology develops targeted therapies for women’s cancers, with a focus on ER+/HER2- breast cancer. Its lead candidate palazestrant (OP-1250) is a dual CERAN/SERD that blocks estrogen signaling and promotes estrogen receptor degradation. The company is running a Phase 3 trial of palazestrant in combination with CDK4/6 inhibitors and has a collaboration with Novartis to test the therapy with ribociclib and everolimus. A second program, a KAT6 inhibitor, is in preclinical development, targeting epigenetic regulation.

Company Size

51-200

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2007

Get referred to Olema Oncology

See people who can refer or advise you

Simplify's Take

What believers are saying

OPERA-01 completed enrollment August 10, 2026; topline data arrive first quarter 2027.
Bayer deal started May 26, 2026, funding OP-3136 combination work without Olema paying drug supply.
Jason O'Byrne joined August 13, 2026, strengthening finance after Shane Kovacs's January departure.

What critics are saying

OPERA-01 slipped from fall 2026 to first quarter 2027, postponing any filing until 2028.
Second-quarter 2026 net loss hit $63.2 million; cash fell to $461.1 million.
Ra Capital, Jennison, and Polar exited in Q2 2026, signaling late-stage skepticism.

What makes Olema Oncology unique

Palazestrant blocks wild-type and mutant ER, separating Olema from weaker SERDs.
OP-3136 adds a KAT6 axis, giving Olema a second endocrine-resistance lever.
Novartis and Bayer collaborations validate partner interest around Olema's combination strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
401(k) Retirement Plan
Remote Work Options
Paid Vacation
Flexible Work Hours
Hybrid Work Options
Stock Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Home Office Stipend
Professional Development Budget

Company News

GlobeNewswire

Oct 2nd, 2026

Olema Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4).

Olema Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4). October 02, 2026 16:30 ET | Source: Olema Oncology SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to six new employees to purchase an aggregate of 235,950 shares of the Company's common stock, effective as of October 1, 2026. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of $8.27 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on October 1, 2026. The stock options are subject to the terms of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com. Media and Investor Relations Contact Courtney O'Konek Vice President, Corporate Communications Olema Oncology [email protected]

Associated Press

Sep 2nd, 2026

Olema Oncology grants CFO 650,000 stock options at $10.56 per share

Olema Oncology granted Jason V. O'Byrne, its new chief financial officer, stock options to purchase 650,000 shares of the company's common stock as an employment inducement award. The grant, effective 1 September 2026, has an exercise price of $10.56 per share, matching Nasdaq's last reported sale price on that date. The options vest over four years, with 25% vesting on 11 August 2027 and the remainder vesting in 36 equal monthly instalments over the following three years, subject to continuous employment. O'Byrne's appointment as CFO became effective 11 August 2026. The award was approved by Olema's Compensation Committee and granted under the company's 2022 Inducement Plan. Olema Oncology is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer.

Quiver Quantitative

Sep 2nd, 2026

Olema Pharmaceuticals grants inducement stock options to newly appointed CFO Jason V. O'Byrne.

Olema Pharmaceuticals grants inducement stock options to newly appointed CFO Jason V. O'Byrne. Posted: 1 day, 9 hours ago / Sept. 2, 2026 8:40 p.m. UTC Olema Pharmaceuticals appointed Jason V. O'Byrne as CFO, granting him 650,000 stock options effective September 1, 2026. Quiver AI summary. Olema Pharmaceuticals, Inc. has announced the appointment of Jason V. O'Byrne as Chief Financial Officer, effective August 11, 2026. To incentivize his role, the company granted him an employment inducement award that includes stock options to purchase 650,000 shares at an exercise price of $10.56 per share, based on the latest Nasdaq reporting. The stock options will vest over four years, with an initial 25 percent vesting on August 11, 2027, followed by monthly vesting. This grant aligns with Nasdaq regulations and is part of Olema's 2022 Inducement Plan. Olema is focused on developing innovative treatments for breast cancer, including the lead candidate palazestrant, currently in Phase 3 trials, and OP-3136, which is in Phase 1 trials. The company operates out of San Francisco and Cambridge, Massachusetts. Potential positives. * Olema Pharmaceuticals appointed Jason V. O'Byrne as Chief Financial Officer, indicating a strategic move to strengthen the company's financial leadership. * The company granted an employment inducement award of 650,000 stock options to Mr. O'Byrne, demonstrating confidence in his capabilities and aligning his interests with shareholders. * The stock options are set at an exercise price equal to the last reported sale price, encouraging performance that aligns with market expectations. * Olema's ongoing commitment to developing innovative therapies for breast cancer, including their lead product candidate, palazestrant, underlines the company's focus on advancing significant medical solutions. Potential negatives. * Granting a significant stock option package (650,000 shares) to the new CFO may raise concerns among investors regarding the company's compensation practices, especially at a time when the company is still in the clinical stage and may not yet be financially stable. * The substantial vesting period for the stock options (four years) could be viewed negatively, as it may imply the need for long-term incentives to retain leadership amidst ongoing challenges in clinical trials and commercialization efforts. * The mention of the employment inducement award might distract from Olema's clinical updates and progress on drug development, potentially raising concerns about prioritization and resource allocation within the company. Faq. Who is Olema Pharmaceuticals? Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and beyond. What recent appointment did Olema announce? Olema announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. What is the stock option grant for Jason O'Byrne? The stock option grant consists of 650,000 shares with an exercise price of $10.56 per share. How does the stock option vest? The stock options vest over four years, with 25% vesting on August 11, 2027, and the remainder in monthly installments. What are Olema's lead product candidates? Olema's lead product candidates include palazestrant (OP-1250) and OP-3136, targeting endocrine-driven cancers. Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here. EARLY ACCESS Receive OLMA Data Alerts Real-time alerts on filings, insider trades, and market signals - before everyone else. $OLMA insider trading activity. $OLMA insiders have traded $OLMA stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales. * SHAWNTE MITCHELL (CHIEF LEGAL OFFICER) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $606,352. * CYRUS HARMON has made 0 purchases and 2 sales selling 25,000 shares for an estimated $291,162. To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint. $OLMA hedge fund activity. We have seen 94 institutional investors add shares of $OLMA stock to their portfolio, and 131 decrease their positions in their most recent quarter. Here are some of the largest recent moves: * RA CAPITAL MANAGEMENT, L.P. removed 2,600,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $32,526,000 * JENNISON ASSOCIATES LLC removed 1,822,123 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,794,758 * FMR LLC added 1,756,217 shares (+16.9%) to their portfolio in Q2 2026, for an estimated $21,970,274 * CORMORANT ASSET MANAGEMENT, LP removed 1,750,000 shares (-44.9%) from their portfolio in Q2 2026, for an estimated $21,892,500 * POLAR CAPITAL HOLDINGS PLC removed 1,602,970 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,053,154 * DEEP TRACK CAPITAL, LP added 1,500,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $18,765,000 * FRANKLIN RESOURCES INC added 1,130,629 shares (+92.8%) to their portfolio in Q2 2026, for an estimated $14,144,168 To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint. $OLMA price targets. Multiple analysts have issued price targets for $OLMA recently. We have seen 6 analysts offer price targets for $OLMA in the last 6 months, with a median target of $39.0. Here are some recent targets: * Brad Canino from Guggenheim set a target price of $35.0 on 05/13/2026 * Dennis Ding from Jefferies set a target price of $40.0 on 03/19/2026 * Richard Law from Goldman Sachs set a target price of $27.0 on 03/18/2026 * Anupam Rama from JP Morgan set a target price of $58.0 on 03/18/2026 * Yigal Nochomovitz from Citigroup set a target price of $62.0 on 03/17/2026 * Emily Bodnar from HC Wainwright & Co. set a target price of $38.0 on 03/09/2026 Full release. SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that, in connection with the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026, the Company granted Mr. O'Byrne an employment inducement award consisting of stock options to purchase 650,000 shares of the Company's common stock, with an effective grant date of September 1, 2026 and an exercise price of $10.56 per share, equal to the last reported sale price of the Company's common stock as reported by Nasdaq on September 1, 2026. The award was approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan. The stock options vest over four years, with 25 percent vesting on August 11, 2027 and the remainder vesting in 36 equal monthly installments over the following three years, subject to continuous employment as of such vesting dates. Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com. Media and Investor Relations Contact Courtney O'Konek Vice President, Corporate Communications Olema Oncology [email protected]

BioCentury

Aug 13th, 2026

Vir CFO O'Byrne joining Olema.

Vir CFO O'Byrne joining Olema. Plus: changes at zenas, kamada and more. By BioCentury Staff August 13, 2026 5:12 PM PDT Jason O'Byrne has joined breast cancer company Olema Pharmaceuticals Inc. (NASDAQ:OLMA) as CFO from Vir Biotechnology Inc. (NASDAQ:VIR), where he held the same role. O'Byrne was also CFO of Caribou Biosciences Inc. (NASDAQ:CRBU) and SVP of Finance at Astellas Pharma Inc. (Tokyo:4503)... Just want immediate access to this one article? Purchase it now.

LOPJLB

Aug 12th, 2026

Olema Pharmaceuticals (OLMA) - pivotal breast-cancer data delay triggers **SELL** signal amid crisis regime.

Olema Pharmaceuticals (OLMA) - pivotal breast-cancer data delay triggers **SELL** signal amid crisis regime. OLMA SELL CRISIS sell flip OLMA Olema Pharmaceuticals, Inc. $10.13 -15.16% LOPJLB.COM Olema Pharmaceuticals closed at $10.43, down 12.65 % on the 2026-08-11 session (Tuesday, US session). The steep decline follows the company's announcement that pivotal Phase 2/3 data for its lead breast-cancer candidate, OP-1250, will not be available until 2027, a timeline shift that has intensified the firm's already fragile financial profile. News & catalysts. * Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027 - Benzinga, 2026-08-11 14:27:24. The release explained that additional enrollment and a stronger statistical powering are required, pushing any regulatory filing to 2028. * Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA(R)(darolutamide) in Metastatic Castration-Resistant Prostate Cancer - GlobeNewswire, 2026-05-26 07:00:00. The partnership expands Olema's pipeline beyond women's oncology but does not offset near-term cash-burn. * Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting - GlobeNewswire, 2026-05-21 17:00:00. Early-stage safety and activity signals were presented, but the path to pivotal trials remains long. * Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript - Seeking Alpha, 2026-06-09 21:22:12. Executives highlighted OP-1250 as a potential first-in-class estrogen-receptor degrader and reiterated reliance on external financing through 2027. * Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire, 2026-08-04 16:30:00. * Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire, 2026-06-02 16:30:00. * Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire, 2026-05-19 16:30:00. These releases collectively shape the short-term outlook: the data delay is the dominant negative catalyst, while the Bayer collaboration and early Phase 1 read-outs provide modest upside narratives that are unlikely to offset the cash-burn pressure. Fundamentals and valuation. FINANCIAL HISTORY Live from OLMA · same charts as the stock page

Olema Oncology

Executive Assistant - Supporting Chief Financial Officer

About the job